N(6)-Carboxymethyllysine.

Carnosine is a histidine dipeptide that reacts with glyoxal and methylglyoxal before they can modify protein lysine residues into carboxymethyllysine. It is the most studied natural carbonyl trap for this chemistry.

Pyridoxamine traps reactive dicarbonyl intermediates and blocks the step that converts an Amadori product into carboxymethyllysine. It is the classic post-Amadori inhibitor in this pathway.

Benfotiamine raises transketolase activity, which pulls triose phosphates into the pentose phosphate route and away from forming the dicarbonyls that generate carboxymethyllysine. The action is upstream of the modification itself.

Carboxymethyllysine forms through an oxidative route from glycated lysine, so the reaction depends on local oxidant load. Lipoic acid regenerates the thiol pool that keeps that load down.

Anserine is the methylated analogue of carnosine and reacts with the same reactive carbonyl species. It resists carnosinase breakdown better, so it persists longer in circulation.

The glyoxalase system clears methylglyoxal, a principal dicarbonyl precursor of advanced glycation end products, and glyoxalase I requires glutathione as a stoichiometric cofactor that is regenerated by glyoxalase II. Glutathione availability therefore sets the throughput of the main enzymatic route that removes glycating dicarbonyls. This is settled enzymology, not a supplement trial result.

Cysteine is the rate-limiting amino acid for glutathione synthesis, and glutathione is the required cofactor for glyoxalase I. Cysteine supply therefore sits one step upstream of dicarbonyl clearance. Free cysteine thiols also scavenge reactive carbonyls directly in solution.

N-acetylcysteine is a cysteine delivery form used because free cysteine is unstable and poorly tolerated, and it feeds the same glutathione synthesis step. The thiol group also reacts with reactive carbonyl species directly. The pathway is established; what a given oral dose does to measured glycation adduct levels in people is not.

Pyridoxal and pyridoxamine forms of vitamin B6 carry carbonyl-reactive groups that trap reactive dicarbonyl intermediates before they can modify a lysine residue. Pyridoxamine specifically is the form studied as a post-Amadori inhibitor of adduct formation. Ordinary pyridoxine is converted in the body to the active forms, so it is an upstream input rather than a direct trap.

Thiamine pyrophosphate is the cofactor for transketolase, which diverts glyceraldehyde-3-phosphate and fructose-6-phosphate away from the triose phosphates that spontaneously generate methylglyoxal. More transketolase activity means less dicarbonyl formed upstream of any adduct. Benfotiamine, already stored against this ingredient, is a lipid-soluble form of the same vitamin, so the two rows describe one pathway.

N6-carboxymethyllysine is formed on the epsilon amino group of a lysine residue, so lysine is the structural substrate the adduct is built from. Free lysine can also compete with protein-bound lysine for reactive carbonyls, acting as a sacrificial target in solution. The relationship is substrate-level chemistry and the direction of any net effect in a person has not been established.

Arginine residues are the other major glycation target, forming hydroimidazolone adducts with methylglyoxal, which is why arginine and lysine adducts are usually measured together. Free arginine can act as a competing carbonyl target in the same way free lysine does. This is adduct chemistry rather than an outcome.

Taurine reacts with reactive carbonyl species through its amino group and has been described as a carbonyl scavenger in laboratory systems. It also stabilises the taurine-conjugated forms of some reactive intermediates. The chemistry is characterised in vitro; nothing measured here shows an effect on adduct load in people.

Flavonoids including quercetin trap methylglyoxal by forming adducts at the electron-rich A ring, which is a well described reaction in food chemistry and in cell systems. Removing the dicarbonyl upstream reduces the pool available to modify lysine residues. The evidence is chemical and preclinical rather than clinical.

Epigallocatechin gallate traps methylglyoxal and glyoxal rapidly in solution and is one of the most studied dietary dicarbonyl scavengers in food systems. Much of the demonstrated activity is in food matrices during cooking rather than inside the body. Read the connection as reaction chemistry that is well established and human relevance that is not.

Resveratrol has been reported to trap methylglyoxal and to influence glyoxalase expression in cell systems. Both routes point the same direction, upstream of adduct formation. This is preclinical work in cells, and no human adduct measurement here supports it.

Curcumin's beta-diketone moiety reacts with reactive carbonyls and the compound has been studied as a glycation inhibitor in laboratory models. Its own absorption is low without a delivery aid, which limits how far the in vitro chemistry can be extended. Mechanistic, not clinical.

Zinc is a structural cofactor in several carbonyl-metabolising enzymes and influences metal-catalysed oxidation chemistry that contributes to the oxidative branch of adduct formation. The connection is indirect and runs through more than one step. It is background biochemistry rather than a supplement pairing with measured output.

Ascorbate suppresses metal-catalysed oxidation that drives the oxidative route to carboxymethyllysine, but ascorbate itself degrades to dehydroascorbate and then to dicarbonyls that can glycate proteins, a process called ascorbylation. The net direction depends on the redox conditions present. This is one of the few places where a general antioxidant assumption does not hold, and it should be stated rather than smoothed over.